Athersys (ATHX) Tops Q2 EPS by 1c

Athersys (NASDAQ: ATHX) reported Q2 EPS of ($0.06), $0.01 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $700 thousand versus the consensus estimate of $550 thousand.

“We are pleased to have received the EMA positive opinion for our pivotal MASTERS-2 stroke study and the Fast Track Designation from the FDA earlier in the quarter,” commented Dr. Gil Van Bokkelen, Chairman & CEO at Athersys. “As a result, we have now successfully established regulatory alignment and clarity with respect to the development and approval path for MultiStem® therapy for ischemic stroke for three major pharmaceutical markets – the U.S., Europe and Japan.

For earnings history and earnings-related data on Athersys (ATHX) click here.

You May Also Be Interested In

• RXO shares soar as C.H. Robinson announces $5.8B cash and stock buyout
• NeuroOne reports 38% Q4 revenue growth, lands $4.5M purchase order
• McCormick & Co. (MKC) Tops Q3 EPS by 10c, Beats on Revenue; Offers EPS Guidance